The FDA has taken a significant step forward in cancer treatment by approving Cabometyx for patients aged 12 and older suffering from certain neuroendocrine tumors. This decision opens new avenues for managing pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET).
Treatment Overview
Cabometyx, containing the active ingredient cabozantinib, is now approved for both adult and pediatric patients with previously treated, unresectable, locally advanced, or metastatic well-differentiated pNET and epNET. This approval represents a vital advancement in the therapeutic landscape for these specific types of neuroendocrine tumors.
The CABINET Trial
The efficacy of Cabometyx for neuroendocrine tumors was established in the phase 3 CABINET trial. This comprehensive study involved two cohorts: one focusing on pNET and the other on epNET.
In the pNET cohort, 99 patients participated, with half receiving Cabometyx at a dose of 60 milligrams daily and the other half receiving a placebo. Notably, the median progression-free survival in the Cabometyx group was recorded at 13.8 months, compared to just 3.3 months in the placebo group. The objective response rate was also promising, with 18% of patients in the Cabometyx arm showing a response versus none in the placebo arm.
Outcomes in the epNET Cohort
The epNET cohort comprised 199 patients, demonstrating a median progression-free survival of 8.5 months for those treated with Cabometyx, compared to 4.2 months for those on placebo. The objective response rate was lower at 5% for the Cabometyx group. As with the pNET cohort, overall survival data were not fully mature, showing 83 deaths in the Cabometyx group and 40 in the placebo group. A noteworthy observation was that 37% of patients in the placebo arm transitioned to Cabometyx treatment, potentially influencing survival results.
Understanding Key Terms
Progression-free survival refers to the duration a patient lives without the disease worsening or spreading. The objective response rate indicates the percentage of patients experiencing either partial or complete responses to treatment. Overall survival encompasses the total time patients live, regardless of their disease status.
Safety Profile and Dosage Recommendations
The FDA confirmed that the safety profile of Cabometyx aligns with its approved labeling. For both adults and pediatric patients weighing at least 40 kilograms, the recommended daily dose is 60 milligrams. For younger patients under this weight threshold, a dosage of 40 milligrams daily is advised until disease progression or intolerable side effects occur.
Previous Approvals and Future Potential
Cabometyx has a history of FDA approvals for other conditions, including thyroid cancer and renal cell carcinoma. In August 2024, a supplemental new drug application for Cabometyx targeting pancreatic neuroendocrine tumors was accepted, highlighting its expanding role in treating complex cancers.
Expert Insights
Dr. Jonathan R. Strosberg, a prominent figure in neuroendocrine tumor management and a professor at Moffitt Cancer Center, has discussed the implications of the CABINET trial findings. He emphasizes that Cabometyx functions as an oral tyrosine kinase inhibitor, primarily targeting VEGFR, but also affecting other receptors such as MET.
Dr. Strosberg notes the historical context, stating that while Sutent has been available for over a decade for pancreatic NETs, Cabometyx could represent a first-in-class option for patients with progressive gastrointestinal neuroendocrine tumors, should it gain FDA approval.
Considerations for Safety
While Cabometyx presents promising benefits, it is essential to consider potential side effects. These may include elevated blood pressure, a marginally increased risk of cardiovascular events, hand-foot syndrome, diarrhea, and fatigue. Most patients can tolerate the standard dose of 60 milligrams without significant issues.
Conclusion
The FDA’s approval of Cabometyx for neuroendocrine tumors marks a pivotal moment in oncology, offering renewed hope for patients with limited treatment options. As the understanding of these complex tumors expands, so too does the potential for innovative therapies. The ongoing research and clinical trials will undoubtedly continue to shape the landscape of neuroendocrine tumor management.
- Cabometyx is now approved for patients aged 12 and older with certain neuroendocrine tumors.
- The CABINET trial demonstrated significant efficacy in progression-free survival.
- Safety profiles are consistent with previous uses of Cabometyx in other cancers.
- The approval highlights a growing arsenal of treatments for complex cancer types.
- Expert insights underline the importance of innovative therapies in managing neuroendocrine tumors.
Read more → www.curetoday.com